Josh Bilenker
Fortune : 66 000 $ au 31/05/2026
Fortune : 66 000 $ au 31/05/2026
Joshua H.
Bilenker was the founder of Treeline Biosciences, Inc. (2021, Chief Executive Officer) and Loxo Oncology, Inc. (2013, President, Chief Executive Officer, CFO & Director).
Dr. Bilenker is currently an Independent Director at Sana Biotechnology, Inc. (2020 - present).
Former positions include Director at LENSAR, Inc., Independent Non-Executive Director at ViewRay Technologies, Inc., Independent Director at Sorrento Tech, Inc. (2012 - 2015), Independent Director at ViewRay, Inc. (2008 - 2017), Director at BioEnterprise Corp., Independent Director at T2 Biosystems, Inc. (2014 - 2017), Director at National Comprehensive Cancer Network Foundation, Independent Director at Gossamer Bio, Inc. (2018 - 2023), Director at Roka Bioscience, Inc. (2012 - 2015), Operating Partner at Aisling Capital LLC (2006 - 2019), Chief Medical Officer at US Food & Drug Administration (2004 - 2006), and Board Observer at Aragon Pharmaceuticals, Inc. Formerly Head-Loxo Oncology Research at Eli Lilly & Co. (2019 - 2021).
Education includes an undergraduate degree from Princeton University (1994) and a doctorate from The Johns Hopkins University School of Medicine (1999).
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SANA BIOTECHNOLOGY, INC. 0,01 % | 04/06/2026 | 20 000 ( 0,01 % ) | 66 000 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Directeur/Membre du Conseil | 01/12/2020 |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Develops molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates for cancer, autoimmune and neurological diseases | Directeur Général | 01/04/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
| GOSSAMER BIO, INC. | Directeur/Membre du Conseil | 08/06/2023 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2021 |
Aisling Capital LLC
Aisling Capital LLC Investment ManagersFinance Aisling Capital invests in both private and public companies located in the Unites States. The firm targets companies operating in the fields of developing & commercializing important and innovative healthcare products, services & technologies sectors and industries. It provides financing for royalty deals, large cap leveraged buyout, seed, early and late stage capital requirements in the form of equity and debt. | Private Equity Investor | 01/12/2019 |
| LOXO ONCOLOGY INC | Directeur Général | 01/02/2019 |
| VIEWRAY SYSTEMS, INC. | Directeur/Membre du Conseil | 01/06/2017 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 18 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
LENSAR, Inc.
LENSAR, Inc. Medical SpecialtiesHealth Technology Develops femtosecond laser technologies for refractive cataract surgery | Health Technology |
ViewRay Technologies, Inc.
ViewRay Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Develops radiation therapy technology for the treatment of cancer | Commercial Services |
Aisling Capital LLC
Aisling Capital LLC Investment ManagersFinance Aisling Capital invests in both private and public companies located in the Unites States. The firm targets companies operating in the fields of developing & commercializing important and innovative healthcare products, services & technologies sectors and industries. It provides financing for royalty deals, large cap leveraged buyout, seed, early and late stage capital requirements in the form of equity and debt. | Finance |
Sorrento Tech, Inc.
Sorrento Tech, Inc. Medical SpecialtiesHealth Technology Develops molecular assays and instrument systems for the food safety industry | Health Technology |
ViewRay, Inc.
ViewRay, Inc. Medical SpecialtiesHealth Technology Designs, manufactures and markets the meridian radiation therapy system | Health Technology |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
BioEnterprise Corp.
BioEnterprise Corp. Miscellaneous Commercial ServicesCommercial Services Initiates for start up funding, and networking information, recruitment and emerging support firms | Commercial Services |
T2 Biosystems, Inc.
T2 Biosystems, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and markets in-vitro diagnostic products | Health Technology |
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
National Comprehensive Cancer Network Foundation | |
Loxo Oncology, Inc.
Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops medicine for cancer treatment | Health Technology |
The Johns Hopkins University School of Medicine
The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gossamer Bio, Inc.
Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Sana Biotechnology, Inc.
Sana Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnological company which creates and delivers engineered cells as medicine for patients | Health Technology |
Roka Bioscience, Inc.
Roka Bioscience, Inc. BiotechnologyHealth Technology Develops highly accurate molecular assays and instrument systems | Health Technology |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Develops molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates for cancer, autoimmune and neurological diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national